From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
The treatment of scrotal cancer should primarily involve Mohs Micrographic Surgery (MMS) as it may improve oncologic outcomes and decrease local post-operative reconstructive issues compared to wide local excision, as suggested by the most recent study 1. When considering treatment options for scrotal cancer, it is essential to prioritize approaches that minimize morbidity and mortality while maintaining quality of life.
- The use of MMS for scrotal cutaneous malignancy, such as squamous cell carcinoma (SCC) and extramammary Paget's Disease (EMPD), has shown promising results with low recurrence rates and minimal local wound complications 1.
- In contrast, traditional wide local excision may result in significant scrotal defects, potentially leading to more extensive reconstructive surgeries and increased morbidity.
- The study by 1 highlights the importance of referring patients with scrotal cutaneous malignancy to centers with MMS capabilities to improve outcomes.
- While other studies, such as 2, 3, 4, and 5, discuss various surgical approaches, including wide local excision and organ-sparing surgeries, the most recent and highest quality evidence supports the use of MMS as a preferred treatment option for scrotal cancer.
- Treatment planning should be multidisciplinary, taking into account the patient's overall health status, disease extent, and potential for lymph node involvement or metastasis.
- Regular follow-up is crucial to monitor for recurrence and adjust treatment plans as necessary.